top of page


FDA approves STADA and Xbrane Lucamzi ranibizumab biosimilar for retinal diseases
The FDA has approved Lucamzi, a ranibizumab biosimilar developed by Xbrane Biopharma and commercialised through STADA, expanding treatment competition in retinal diseases.

nuaxia
Oct 302 min read


STADA and SBP Group partner on Keytruda biosimilar and up to three additional biosimilar programmes
STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

nuaxia
Sep 292 min read
bottom of page